Bibliography
- Evans WE , McLeodHL: Pharmacogenomics – drug disposition, drug targets, and side effects.N. Engl. J. Med.348, 538–549 (2003).
- Marsh S , McLeodHL: Cancer pharmacogenetics.Br. J. Cancer90, 8–11 (2004).
- Watters JW , McLeodHL: Recent advances in the pharmacogenetics of cancer chemotherapy.Curr. Opin. Mol. Ther.4, 565–571 (2002).
- Illmer T , SchulerUS, ThiedeC et al.: MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients.Cancer Res.62, 4955–4962 (2002).
- Lenz HJ : The use and development of germline polymorphisms in clinical oncology.J. Clin. Oncol.22, 2519–2521 (2004).
- McLeod HL , KingCR, MarshS: Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies.Clin. Colorectal Cancer 4(Suppl. 1), S43–S47 (2004).
- Marsh S , McLeodHL: Pharmacogenetics of irinotecan toxicity.Pharmacogenomics5, 835–843 (2004).
- Yu J , MarshS, AhluwaliaR, McLeodHL: Ferredoxin reductase: pharmacogenomic assessment in colorectal cancer.Cancer Res.63, 6170–6173 (2003).
- Marsh S , Collie-DuguidES, LiT, LiuX, McLeodHL: Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations.Genomics58, 310–312 (1999).
- Marsh S , XiaoM, YuJ et al.: Pharmacogenomic assessment of carboxylesterases 1 and 2.Genomics84, 661–668 (2004).
- Marsh S , KingCR, GarsaAA, McLeodHL: Pyrosequencing of clinically relevant polymorphisms.Methods Mol. Biol.311, 97–114 (2005).
- Boland CR , ThibodeauSN, HamiltonSR et al.: A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.Cancer Res.58, 5248–5257 (1998).
- Grady WM : Genomic instability and colon cancer.Cancer Metastasis Rev.23, 11–27 (2004).
- Buttin BM , PowellMA, MutchDG et al.: Increased risk for hereditary nonpolyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability-positive endometrial carcinoma lacking MLH1 promoter methylation.Clin. Cancer Res.10, 481–490 (2004).
- Rooney PH , MurrayGI, StevensonDA, HaitesNE, CassidyJ, McLeodHL: Comparative genomic hybridization and chromosomal instability in solid tumours.Br. J. Cancer80, 862–873 (1999).
- Mort R , MoL, McEwanC, MeltonDW: Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer.Br. J. Cancer89, 333–337 (2003).
- Rae JM , CorderoKE, ScheysJO, Lippman ME, Flockhart DA, Johnson MD: Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples.Pharmacogenetics13, 501–507 (2003).
- Paez JG , JannePA, LeeJC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.Science304, 1497–1500 (2004).
- Lynch TJ , BellDW, SordellaR et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib.N. Engl. J. Med.350, 2129–2139 (2004).
- Hurst CD , FieglerH, CarrP, WilliamsS, CarterNP, KnowlesMA: High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization.Oncogene23, 2250–2263 (2004).
- McLeod HL , MarshS: Pharmacogenetics goes 3D.Nature Genet.37, 794–795 (2005).
- Cheng Q , YangW, RaimondiSC, PuiCH, RellingMV, EvansWE: Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes.Nature Genet.37, 878–882 (2005).
Website
- http://pharmacogenetics.wustl.edu Pharmacogenetics Research Network Comprehensive Research on Expressed Alleles in Therapeutic Evaluation website (Accessed November2005).